Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/28/2025

Managing Nausea in Patients Taking Vraylar (Cariprazine)

First-Line Treatment Options

  • The American Gastroenterological Association recommends 5-HT3 receptor antagonists such as ondansetron (4-8 mg twice or three times daily) as the most effective first-line treatment option for patients experiencing nausea while taking Vraylar (cariprazine) 1, 2
  • Ondansetron (4-8 mg twice or three times daily) blocks serotonin receptors in the chemoreceptor trigger zone and inhibits vagal afferents, providing effective relief for medication-induced nausea 1, 2
  • Granisetron (1 mg twice daily or 34.3 mg transdermal patch weekly) offers similar efficacy to ondansetron with different administration options 1, 2

Non-Pharmacological Approaches

  • Eating small, frequent meals rather than large meals can help alleviate nausea in patients taking Vraylar (cariprazine) 5
  • Choosing foods at room temperature rather than hot foods can help alleviate nausea in patients taking Vraylar (cariprazine) 5
  • Avoiding strong odors that may trigger nausea can help alleviate nausea in patients taking Vraylar (cariprazine) 5
  • Ensuring adequate hydration throughout the day can help alleviate nausea in patients taking Vraylar (cariprazine) 3

Monitoring and Follow-up

  • Assess response to antiemetic therapy within 24-48 hours to determine effectiveness of treatment 5
  • If nausea persists for more than one week despite appropriate management, reassess for other potential causes 4, 5
  • Monitor for adverse effects of antiemetic medications, such as sedation with antihistamines or QT prolongation with ondansetron at higher doses 1, 2

REFERENCES

3

Management of Nausea and Vomiting [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013